AN2 Therapeutics (ANTX) Other Non Operating Income (2021 - 2024)

AN2 Therapeutics (ANTX) has 4 years of Other Non Operating Income data on file, last reported at $1.3 million in Q3 2024.

• On a quarterly basis, Other Non Operating Income fell 13.99% year-over-year to $1.3 million in Q3 2024; TTM through Dec 2024 was $1.3 million, a 2848.84% increase from a year earlier, with the FY2025 full-year figure at $1000.0, changed 0.0% from the prior year.
• Other Non Operating Income for Q3 2024 stood at $1.3 million, up from $1000.0 in the prior quarter.
• Over the last five years, Other Non Operating Income for ANTX reached as high as $1.5 million in Q3 2023 and fell as low as -$2.9 million in Q4 2023.
• Historically, Other Non Operating Income has averaged $198384.6 across 4 years, with a median of $213000.0 in 2022.
• Across the five-year window, Other Non Operating Income surged 2781.82% in 2022 and tumbled 564.2% in 2023, its largest moves.
• Year by year, Other Non Operating Income stood at $22000.0 in 2021, then jumped by 2781.82% to $634000.0 in 2022, then tumbled by 564.2% to -$2.9 million in 2023, then jumped by 143.05% to $1.3 million in 2024.
• Per Business Quant data, the three most recent Other Non Operating Income figures were $1.3 million in Q3 2024, $1000.0 in Q1 2024, and -$2.9 million in Q4 2023.